Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

NCT00193050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Gemcitabine
DRUG: Epirubicin
DRUG: Docetaxel

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]
[object Object]